Delcath Systems (DCTH) Q1 2026 earnings review
Top-Line Breakout Masked by R&D-Driven Profitability Reversal
Delcath delivered a strong $25.0M top line, up 26% YoY, finally breaking out of the revenue plateau seen in the second half of 2025. The publication of the CHOPIN trial data in The Lancet Oncology is actively changing prescribing patterns, driving an impressive 36% surge in HEPZATO volume. However, the bottom line tells a story of deliberate sacrifice: management's aggressive pivot toward larger clinical indications caused R&D to nearly double, pushing Net Income into reversing territory (a $1.1M loss). With $89.3M in cash and zero debt, Delcath is trading near-term earnings for massive TAM expansion, but the disconnect between volume growth (36%) and revenue growth (26%) reveals persistent pricing headwinds.
🐂 Bull Case
The full CHOPIN trial publication in The Lancet Oncology and immediate inclusion in ESMO-EURACAN practice guidelines catalyzed a 36% YoY jump in HEPZATO volume, validating the combination therapy approach.
After stalling around the $20.5M mark in H2 2025 due to summer seasonality and 340B pricing adjustments, Q1 26 revenue surged 20% sequentially to a record $25.0M.
🐻 Bear Case
Net income reversed from a $1.1M profit in 25Q1 to a $1.1M loss in 26Q1, driven by a 96% surge in R&D expenses as the company funds its new clinical trials.
While volume grew 36%, revenue only grew 26%. This 1000-basis-point gap quantifies the ongoing margin drag from the 340B/NDRA pricing program implemented last year.
⚖️ Verdict: ⚪
Neutral. The commercial execution is excellent and clinical validation is undeniable, but the transition into an intensive R&D investment cycle means profitability will remain under pressure. Investors must be willing to underwrite the cash burn required to target larger cancer indications.
Key Themes
CHOPIN Data Publication Accelerates Adoption
The highly anticipated full results of the CHOPIN trial were published in The Lancet Oncology. Demonstrating that adding ipilimumab and nivolumab to PHP significantly improves progression-free survival is already shifting physician prescribing patterns. Furthermore, the newly published ESMO-EURACAN Clinical Practice Guidelines officially recommended the therapy. This macro-level industry validation is the primary driver behind the 36% YoY volume growth.
Strategic Investment Cycle Crushes Near-Term Profitability
Profitability is rapidly reversing. R&D expenses skyrocketed 96% YoY to $9.8M, up from $5.0M. SG&A increased 16% to $13.1M. Management telegraphed this in prior quarters, explicitly stating they would sacrifice short-term cash flow to fund pipeline expansion (mCRC and mBC trials). While strategic, this level of expense growth completely absorbed the $4.3M gross profit increase, flipping the company into an operating loss of $1.6M.
340B Pricing Headwind Mathematically Proven
The current quarter provides clear evidence of the pricing headwind introduced by the 340B/NDRA program in mid-2025. HEPZATO volume grew 36%, but total revenue only increased 26%. This implies an effective realized price discount of roughly 10%, aligning perfectly with management's prior guidance of a ~10% discount to list price. Volume must continue to significantly outpace revenue expectations to generate meaningful bottom-line growth.
Treatment Center Expansion Tracking Steadily
The company reported 29 active centers, up from 28 at the end of 2025 and 19 a year ago. The methodical scaling of the commercial footprint remains the most reliable leading indicator for future kit volume.
Pipeline Expansion Targeting Massive TAMs
The core thesis for Delcath has shifted from solely commercializing uveal melanoma to leveraging its Hepatic Delivery System (HDS) tech across larger indications. The R&D spend is entirely focused on Phase 2 trials for metastatic colorectal cancer (mCRC) and metastatic breast cancer (mBC)—markets approximately 7x larger than their current indication.
Cash Flow Generation Decelerating
Cash provided by operations fell to $0.9M, decelerating sharply from the $2.2M generated in 25Q1. While still positive, the shrinking cushion leaves less room for error as clinical trial costs continue to mount through 2026.
Other KPIs
Decelerating significantly compared to $7.6 million in 25Q1. This metric perfectly illustrates the operational leverage being consumed by trial expansions and commercial headcount.
Stable. Only slightly down from 86% in 25Q1, indicating that manufacturing efficiency remains intact despite the lower average selling price driven by 340B discounts.
The company aggressively utilized its $25M buyback program, taking advantage of equity pricing to retire shares, enabled by its robust $89.3M cash position.
Guidance
Decelerating YoY growth structurally, but still representing an impressive ~17% increase over the $85.2M generated in FY25. Achievable if the Q1 run-rate of $25M holds steady without summer seasonality disruptions.
Stable. The Q1 actual of 85% falls perfectly within the midpoint of this guidance, suggesting management has high visibility into unit economics.
Stable. Despite guiding for an expected 90% full-year surge in R&D and 50% surge in SG&A, management remains committed to preventing the company from reverting to an EBITDA loss.
Key Questions
Operating Expense Cadence
R&D nearly doubled in Q1. Is this the peak quarterly run-rate for trial expenses, or should we expect sequential increases throughout 2026 as mCRC and mBC enrollment accelerates?
Pricing Stabilization
With the 340B program now fully integrated for almost a year, are the discounts stabilizing at the current ~10% effective rate, or are you seeing mix shifts that could drag realized pricing lower?
Center Capacity Limits
With volume surging 36% and active centers sitting at 29, are any of your top-tier centers hitting physical capacity limits regarding perfusion teams or OR time?